Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Imvotamab by IGM Biosciences for Rheumatoid Arthritis: Likelihood of Approval
Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase...
Imvotamab by IGM Biosciences for Systemic Lupus Erythematosus: Likelihood of Approval
Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData,...
Imvotamab by IGM Biosciences for Idiopathic Inflammatory Myopathy (IIM): Likelihood of Approval
Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Idiopathic Inflammatory Myopathy (IIM). According to...
Imvotamab by IGM Biosciences for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Imvotamab is under clinical development by IGM Biosciences and currently in Phase II for Marginal Zone B-cell Lymphoma. According to...